Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 30

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 30
---
 our global IP strategy generally targets Australia, Canada, Europe, Japan,
and the United States, and sometimes Brazil, China and/or Korea, as targets for extending patent protection under the PCT. Decisions regarding
which countries to extend patent coverage under the PCT is taken on a case-by-case basis, subject to normal business considerations such
as value and return on investment. Given the markets for products we are developing, we consider the foregoing jurisdictions to amount
to “global” coverage as used herein as it relates to IP.

The above disclosures related
to patents and patent applications are subject to change based on strategic patent portfolio building decisions, which may include refiling
and reissue, certain abandonments, including those in favor of continuing patent applications, maturations from provisional to non-provisional
filings, and other regular patent prosecution activities.

Trademarks

The designations INMUNE BIOTM, INB16TM, INKmuneTM,
PSEUDOKINETM, and XProTM are trademarks of INmune Bio Inc. Some or all these trademarks may be protected by applications
pending at the USPTO and other trademark registration authorities globally. As part of the trademark registration process, we may be required
to submit a statement of use evidencing bona fide use of each mark in commerce. By nature of being in the biopharmaceutical business,
certain regulatory requirements must be met in connection with certain products and/or services prior to receiving marketing authorization
from a regulatory agency, and thus it may take some time before products and/or services are offered for sale and a statement of use can
be submitted for perfecting trademark registration. For these reasons, we may be required to obtain extensions of time, or to refile applications,
seeking registration of trademarks. We cannot guarantee that a given trademark application will be allowed or issued in a respective office
for each jurisdiction.

IP License Agreements

Immune Ventures, LLC License Agreement

On October 29, 2015, the Company
entered into an exclusive license agreement (the “INKmune License Agreement”) with Immune Ventures, LLC (“Immune Ventures”).
Pursuant to the INKmune License Agreement, we were granted an exclusive worldwide, sub-licensable, royalty-bearing license to commercialize
INKmune (the “INKmune License”). In consideration for the INKmune License, we are obligated to pay Immune Ventures certain
milestone and royalty payments.

18